MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtct.2025.05.021

Медицинская библиотека · Transplantation and cellular therapy · 2025

Letermovir Primary and Secondary Prophylaxis in Pediatric Recipients of Allogeneic Haematopoietic Stem Cell Transplant.

Vendemini Francesca, De Lorenzo Paola, Romani Francesca, Malandrin Sandro Maria Ivano, Verna Marta, Bonanomi Sonia, Valsecchi Maria Grazia, Lucchini Giovanna, Balduzzi Adriana

СтатьяПеревод в очереди

Аннотация

BACKGROUND

CMV reactivation represents one of the most frequent infectious complications post HSCT. Letermovir is a viral terminate inhibitor which has been approved in adults for the prophylaxis of post HSCT CMV reactivation. Its use in pediatric HSCT recipient was recently approved by US FDA but data on the use of letermovir in children remain limited.

OBJECTIVE(S): We aimed at comparing the incidence of CMV reactivation in a more recent cohort of pediatric HSCT recipients receiving primary or secondary prohylaxis with letermovir with a previous cohort of children receiving no prophylaxis. We analyzed the risk factors for CMV reactivation among IgG seropositive recipients and the role of CMV reactivation on treatment related mortality/overall survival.

STUDY

DESIGN

This is a single center retrospective study which enrolled all consecutive patients aged <21 years who underwent allogeneic HSCT between 1 January 1, 2014 and October 31, 2023 at the pediatric HSCT Unit of the Fondazione IRCCS San Gerardo dei Tintori in Monza

RESULTS

287 patients who received 308 HSCT were analyzed. Three months cumulative incidence of CMV reactivation was 29.5% (95% CI: 24.3-35) in the standard cohort versus 3.7% (95% CI: 0.3-16.3) in the cohort of patients receiving letermovir as primary prophylaxis (P = .0029). The use of letermovir as well as the use of a HLA-identical donor with no serotherapy, bone marrow as a source of stem cell and the absence of acute GVHD were statistically significant protective factors against CMV reactivation at multivariate analysis. At 3 months after discontinuation of preemptive therapy, the cumulative incidence of CMV reactivation was 0% for the 15 patients receiving letermovir as secondary prophylaxis versus 34.7% (SE 5.8, 95% CI: 23.7-46.0) for the 72 patients not receiving secondary prophylaxis.

CONCLUSIONS

Letermovir is safe and efficacious in preventing CMV reactivation in pediatric patients undergoing HSCT in both primary and secondary prophylaxis.

Для цитирования: Vendemini Francesca, De Lorenzo Paola, Romani Francesca, Malandrin Sandro Maria Ivano, Verna Marta, Bonanomi Sonia, Valsecchi Maria Grazia, Lucchini Giovanna, Balduzzi Adriana. Letermovir Primary and Secondary Prophylaxis in Pediatric Recipients of Allogeneic Haematopoietic Stem Cell Transplant.. Transplantation and cellular therapy. 2025. DOI: 10.1016/j.jtct.2025.05.021.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.